Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Midwestern Regional Medical Center
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female
18 years or older
Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
Biopsy proven diagnosis of invasive adenocarcinoma of the breast
Recommendation for neoadjuvant chemotherapy.
Left Ventricular Ejection Fraction (LVEF) assessment by multigated acquisition scan or echocardiogram within 3 months of entering study
Blood counts:
Absolute Neutrophil Count ≥1200 cells/mm\^3
Platelet count ≥100,000/mm\^3
Hemoglobin ≥10g/dL
Serum creatinine ≤ Upper Limit of Normal (ULN) for the laboratory range
Total bilirubin ≤ ULN for the laboratory range, unless the patient has an elevation \>ULN to 1.5 times the ULN resulting from Gilbert's disease or similar syndrome
Alkaline phosphatase less than or equal to 2.5 x ULN; and
Aspartate aminotransferase (AST) less than or equal to 1.5 x ULN for the laboratory range
If skeletal pain present or alkaline phosphatase \>ULN (but less than or equal to 2.5x ULN), bone scan or Positron Emission Tomography (PET) scan must not demonstrate metastatic disease
AST or alkaline phosphatase greater than ULN, no metastatic disease liver identified by CT, MRI or PET scan
Able to swallow oral medication
Willing to forego naturopathic treatment for the first 2 treatment cycles
Willing to start and continue naturopathic interventions as prescribed
Willing to forego the use of nutritional or botanical supplements during the study
You may not be if
Stage 4 disease
Present treatment with Warfarin.
Synchronous bilateral invasive breast cancer
Treatment including radiation, chemotherapy, and/or targeted therapy for the currently diagnosed breast cancer prior to entering study
Any sex hormonal therapy e.g. birth control, ovarian hormone replacement therapy, etc. during participation in the study)
Continued therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators
Prior history of breast cancer, including Ductal Carcinoma In Situ (subjects with a history of Lobular Carcinoma In Situ are eligible)
Prior therapy with chemotherapy or targeted therapy agents for any malignancy
Cardiac disease that would preclude the use of the certain drugs. This includes but is not confined to:
